ANEB Stock Analysis: Buy, Sell, or Hold?
ANEB - Anebulo Pharmaceuticals, Inc. Common Stock
$0.36
-0.07 (-16.49%)
▼
5d:
-23.89%
30d:
-57.89%
90d:
-84.79%
WAIT
LOW Confidence
Analysis Updated: Feb 27, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When ANEB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ANEB is down 23.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ANEB is down 23.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ANEB is currently trading at $0.36, which is considered fair based on recent price action.
Technical Outlook: Technically, ANEB is in a strong downtrend. The price is currently testing key support at $0.35. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 16.5% recently.
Market Sentiment: ANEB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.00 (+733.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ANEB is in a strong downtrend. The price is currently testing key support at $0.35. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 16.5% recently.
Market Sentiment: ANEB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.00 (+733.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
51/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
76.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BEARISH: Downward momentum (-16.5%)
- BULLISH: Trading 733.3% below Wall St target ($3.00)
- WARNING: Recommendation downgraded due to -23.9% 5-day decline - wait for stabilization
Support & Resistance Levels
Support Level
$0.35
Resistance Level
$0.54
Current Trend
Strong Downtrend
Technical data as of
Feb 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.78
Wall Street Target
$3.00
(+733.3%)
Share & Embed Analysis
Last updated: June 15, 2026 4:12 PM ET
Data refreshes hourly during market hours. Next update: 5:12 PM
Data refreshes hourly during market hours. Next update: 5:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANEB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 62 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 53 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
